{"id":8602,"date":"2023-10-04T12:10:06","date_gmt":"2023-10-04T12:10:06","guid":{"rendered":"https:\/\/mdxcro.com\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/"},"modified":"2026-02-24T11:29:07","modified_gmt":"2026-02-24T11:29:07","slug":"regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda","status":"publish","type":"post","link":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/","title":{"rendered":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA"},"content":{"rendered":"\n<p>The\u00a0<strong>FDA Laboratory Developed Tests regulation<\/strong>\u00a0marks one of the most significant shifts in U.S. diagnostic oversight in decades. The FDA\u2019s new rule phases in full regulation of LDTs over four years, <strong>with no grandfathering<\/strong>. This change elevates the importance of\u00a0<strong>IVD CROs<\/strong>, whose regulatory and clinical expertise will be critical as laboratories adapt to stringent new requirements. The rule represents a major transformation in the U.S. IVD landscape and will reshape how laboratories develop, validate, and maintain LDTs.<\/p>\n\n<h2 class=\"wp-block-heading\">Introduction<\/h2>\n\n<p>On\u00a0<strong>September 29, 2023<\/strong>, the FDA released a groundbreaking <a href=\"https:\/\/www.federalregister.gov\/documents\/2023\/10\/03\/2023-21662\/medical-devices-laboratory-developed-tests\">proposed rule<\/a> that fundamentally redefines how the agency regulates\u00a0<strong>Laboratory\u2011Developed Tests (LDTs)<\/strong>. This proposal shifts LDTs out of decades of enforcement discretion and brings them fully under the FDA\u2019s medical device framework.<\/p>\n\n<p>Because LDTs are a subset of\u00a0<strong>in vitro diagnostic products (IVDs)<\/strong>, the new rule has sweeping implications for clinical laboratories, manufacturers, and the broader diagnostics industry. Under the\u00a0<strong>FDA Laboratory Developed Tests regulation<\/strong>, LDTs will now be treated like other medical devices\u2014requiring quality systems, medical device reporting, registration, listing, and in many cases,\u00a0<strong>premarket review<\/strong>.<\/p>\n\n<p>For stakeholders across the IVD sector, this change is significant.<\/p>\n\n<h2 class=\"wp-block-heading\">Key Points to Consider as the FDA regulates LDTs<\/h2>\n\n<ol class=\"wp-block-list\">\n<li><strong>Expanded Definition of IVDs<\/strong><br\/>The FDA proposes to explicitly classify LDTs as IVDs under 21 CFR 809.3.<br\/>This means LDTs will now fall under the same requirements as traditional IVD medical devices.<\/li>\n\n\n\n<li><strong>Phased, Four\u2011Year Implementation<\/strong><br\/>The FDA will remove enforcement discretion in five stages over a four\u2011year timeline.<br\/>Each stage introduces new regulatory obligations for laboratories.<\/li>\n\n\n\n<li><strong>No Grandfather Clause<\/strong><br\/>The proposal does not exempt existing LDTs. All LDTs (old and new) must eventually comply.<\/li>\n\n\n\n<li><strong>Test Categories Exempt from Enhanced Oversight<\/strong><br\/>Certain test types, including forensic tests and HLA assays, are proposed for exemption.<\/li>\n\n\n\n<li><strong>Public Comment Period<\/strong><br\/>Stakeholders were invited to submit comments through December 4, 2023.<\/li>\n<\/ol>\n\n<h2 class=\"wp-block-heading\">Background on FDA Regulation for LDTs and IVDs<\/h2>\n\n<p>IVDs have traditionally been subject to rigorous regulatory scrutiny under various heads:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>510(k) premarket notification or premarket approval (PMA)<\/li>\n\n\n\n<li>Quality system regulation<\/li>\n\n\n\n<li>Medical device reporting<\/li>\n\n\n\n<li>Registration and listing<\/li>\n\n\n\n<li>Labeling<\/li>\n<\/ul>\n\n<p>LDTs, however, historically operated under\u00a0<strong>enforcement discretion<\/strong>, receiving minimal oversight. This approach was based on the assumption that LDTs were low risk and used primarily within single laboratories.<\/p>\n\n<p>That landscape has changed.<\/p>\n\n<h2 class=\"wp-block-heading\">The Evolving Landscape of LDTs<\/h2>\n\n<p>Over the last 50 years, LDTs have become increasingly complex, widely used, and technically sophisticated. This evolution has driven demand for stronger oversight in areas such as:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Clinical validity<\/li>\n\n\n\n<li>Analytical performance<\/li>\n\n\n\n<li>Manufacturing consistency<\/li>\n\n\n\n<li>Patient safety<\/li>\n<\/ul>\n\n<p>The new\u00a0<strong>FDA Laboratory Developed Tests regulation<\/strong>\u00a0directly responds to these gaps. By redefining LDTs and removing enforcement discretion, the FDA aims to strengthen public health protections.<\/p>\n\n<h2 class=\"wp-block-heading\">The Road Ahead: Key Regulatory Impacts<\/h2>\n\n<p>The phased implementation timeline will introduce major compliance requirements:<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Medical Device Reporting<\/strong><\/h3>\n\n<p>The first enforcement area to take effect.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Quality Systems Regulation<\/strong><\/h3>\n\n<p>Expected three years after publication of the final rule.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Premarket Review<\/strong><\/h3>\n\n<p>Introduced 3.5 to four years after the final rule, starting with high\u2011risk LDTs and expanding to moderate-and-low risk tests.<\/p>\n\n<p>Labs performing LDTs must begin planning\u00a0<strong>now<\/strong>. Clinical and analytical validation, documentation systems, and regulatory processes will all require upgrades.<\/p>\n\n<h2 class=\"wp-block-heading\">Alignment With Europe\u2019s IVDR Rollout<\/h2>\n\n<p>The FDA\u2019s new approach mirrors developments in Europe under the\u00a0<strong><a href=\"https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_6965\">In Vitro Diagnostic Regulation (IVDR)<\/a><\/strong>. The IVDR already applies strict rules to in\u2011house tests and LDTs, requiring:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Complete <a href=\"https:\/\/mdxcro.com\/es\/servicios\/asuntos-regulatorios-documentacion-tecnica\/\">Technical Documentation<\/a><\/li>\n\n\n\n<li>A compliant Quality Management System<\/li>\n\n\n\n<li>Performance evaluation and validation<\/li>\n\n\n\n<li>Adherence to Article 5.5 requirements for in\u2011house devices<\/li>\n<\/ul>\n\n<p>\u00e7Under IVDR, an <a href=\"https:\/\/mdtcro.com\/ivdr-and-mdcg-2023-1-on-ldt\/\">LDT<\/a> cannot be used if an equivalent CE\u2011marked test exists. This forces laboratories to justify in\u2011house development and meet near\u2011manufacturer\u2011level standards.<\/p>\n\n<h2 class=\"wp-block-heading\">Conclusion: An Industry in Transition<\/h2>\n\n<p>As experts in IVD quality, regulatory, and clinical operations,\u00a0<strong>MDx CRO<\/strong>\u00a0encourages laboratories and manufacturers to prepare now for the\u00a0<strong>FDA Laboratory Developed Tests regulation<\/strong>. Although legal challenges may influence the timeline, increased oversight is inevitable, and already fully established within Europe under the IVDR.<\/p>\n\n<p>Stakeholders should submit comments to the FDA by\u00a0<strong>December 4, 2023<\/strong>, and begin strengthening their regulatory systems immediately.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The\u00a0FDA Laboratory Developed Tests regulation\u00a0marks one of the most significant shifts in U.S. diagnostic oversight in decades. The FDA\u2019s new rule phases in full regulation of LDTs over four years, with no grandfathering. This change elevates the importance of\u00a0IVD CROs, whose regulatory and clinical expertise will be critical as laboratories adapt to stringent new requirements. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5915,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[231,227],"tags":[233,234,360,317,373,218,361,367,348,368,364,366,369,365,363,370,371,232,362,372],"resources-sector":[178,182],"class_list":["post-8602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualizaciones-normativas","category-noticias-sobre-ivd","tag-cumplimiento-normativo","tag-diagnostico-in-vitro","tag-dispositivos-medicos","tag-div","tag-documentacion-tecnica","tag-ivdr-es","tag-laboratorios-clinicos","tag-ldt","tag-marcado-ce","tag-mdx-es","tag-politica-de-salud","tag-pruebas-desarrolladas-en-laboratorio","tag-pruebas-medicas","tag-regulacion-de-la-atencion-medica","tag-regulacion-de-la-fda","tag-revision-previa-a-la-comercializacion","tag-salud-publica","tag-seguridad-del-paciente","tag-servicios-de-consultoria","tag-sistema-de-gestion-de-calidad","resources-sector-ivds","resources-sector-laboratories"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO<\/title>\n<meta name=\"description\" content=\"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO\" \/>\n<meta property=\"og:description\" content=\"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"MDx CRO\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T12:10:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T11:29:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2276\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Carlos Galamba\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carlos Galamba\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/\"},\"author\":{\"name\":\"Carlos Galamba\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/person\\\/757ac74b94d37b0b3992676bb7e868e4\"},\"headline\":\"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA\",\"datePublished\":\"2023-10-04T12:10:06+00:00\",\"dateModified\":\"2026-02-24T11:29:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/\"},\"wordCount\":677,\"publisher\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2023\\\/01\\\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg\",\"keywords\":[\"Cumplimiento normativo\",\"Diagn\u00f3stico in vitro\",\"dispositivos m\u00e9dicos\",\"DIV\",\"Documentaci\u00f3n t\u00e9cnica\",\"IVDR\",\"Laboratorios cl\u00ednicos\",\"LDT\",\"Marcado CE\",\"MDx\",\"Pol\u00edtica de salud\",\"Pruebas desarrolladas en laboratorio\",\"Pruebas m\u00e9dicas\",\"Regulaci\u00f3n de la atenci\u00f3n m\u00e9dica\",\"Regulaci\u00f3n de la FDA\",\"Revisi\u00f3n previa a la comercializaci\u00f3n\",\"Salud p\u00fablica\",\"Seguridad del paciente\",\"Servicios de consultor\u00eda\",\"Sistema de gesti\u00f3n de calidad\"],\"articleSection\":[\"Actualizaciones normativas\",\"Noticias sobre IVD\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/\",\"name\":\"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2023\\\/01\\\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg\",\"datePublished\":\"2023-10-04T12:10:06+00:00\",\"dateModified\":\"2026-02-24T11:29:07+00:00\",\"description\":\"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2023\\\/01\\\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2023\\\/01\\\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg\",\"width\":2276,\"height\":1280,\"caption\":\"State-of-the-art clinical laboratory setup, poised to adapt to the FDA's proposed rule changes on Laboratory Developed Tests (LDTs)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/ivd-cro\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/\",\"name\":\"MDx CRO\",\"description\":\"Investigaci\u00f3n cl\u00ednica, normativa y control de calidad en tecnolog\u00eda m\u00e9dica y diagn\u00f3stico in vitro\",\"publisher\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\"},\"alternateName\":\"MDx\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\",\"name\":\"CRO de MDx\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/MDX.svg\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/MDX.svg\",\"width\":352,\"height\":114,\"caption\":\"CRO de MDx\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medtech-ivd-cro\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/person\\\/757ac74b94d37b0b3992676bb7e868e4\",\"name\":\"Carlos Galamba\",\"pronouns\":\"he\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Carlos-Galamba-2-96x96.jpg\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Carlos-Galamba-2-96x96.jpg\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Carlos-Galamba-2-96x96.jpg\",\"caption\":\"Carlos Galamba\"},\"description\":\"With more than 18 years of experience in the IVD sector, including hands-on work as a scientist in transfusion medicine and infectious disease diagnostics, and regulatory review experience at BSI, one of the EU's largest Notified Bodies, Carlos Galamba brings a uniquely integrated perspective to IVD regulatory strategy. Their work spans Class C\\\/D IVDs, companion diagnostics, NGS-based assays, and software-based IVDs, with a current advisory role to the European Commission on regulatory matters. At MDx CRO, they lead regulatory strategy for complex IVD programs across EU IVDR, FDA, and global markets.\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/carlos-galamba\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@MDxCRO\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO","description":"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/","og_locale":"es_ES","og_type":"article","og_title":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO","og_description":"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.","og_url":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/","og_site_name":"MDx CRO","article_published_time":"2023-10-04T12:10:06+00:00","article_modified_time":"2026-02-24T11:29:07+00:00","og_image":[{"width":2276,"height":1280,"url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg","type":"image\/jpeg"}],"author":"Carlos Galamba","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Carlos Galamba","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#article","isPartOf":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/"},"author":{"name":"Carlos Galamba","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/person\/757ac74b94d37b0b3992676bb7e868e4"},"headline":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA","datePublished":"2023-10-04T12:10:06+00:00","dateModified":"2026-02-24T11:29:07+00:00","mainEntityOfPage":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/"},"wordCount":677,"publisher":{"@id":"https:\/\/mdxcro.com\/es\/#organization"},"image":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg","keywords":["Cumplimiento normativo","Diagn\u00f3stico in vitro","dispositivos m\u00e9dicos","DIV","Documentaci\u00f3n t\u00e9cnica","IVDR","Laboratorios cl\u00ednicos","LDT","Marcado CE","MDx","Pol\u00edtica de salud","Pruebas desarrolladas en laboratorio","Pruebas m\u00e9dicas","Regulaci\u00f3n de la atenci\u00f3n m\u00e9dica","Regulaci\u00f3n de la FDA","Revisi\u00f3n previa a la comercializaci\u00f3n","Salud p\u00fablica","Seguridad del paciente","Servicios de consultor\u00eda","Sistema de gesti\u00f3n de calidad"],"articleSection":["Actualizaciones normativas","Noticias sobre IVD"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/","url":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/","name":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA | MDx CRO","isPartOf":{"@id":"https:\/\/mdxcro.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#primaryimage"},"image":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg","datePublished":"2023-10-04T12:10:06+00:00","dateModified":"2026-02-24T11:29:07+00:00","description":"La regulaci\u00f3n de las LDT por parte de la FDA y sus efectos en el sector de los DIV. Lea m\u00e1s sobre los cambios clave, los plazos y los paralelismos con el IVDR europeo.","breadcrumb":{"@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#primaryimage","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2023\/01\/What_you_need_to_know_about_in_house_IVD_regulation_in_the_EU-scaled-1.jpeg","width":2276,"height":1280,"caption":"State-of-the-art clinical laboratory setup, poised to adapt to the FDA's proposed rule changes on Laboratory Developed Tests (LDTs)"},{"@type":"BreadcrumbList","@id":"https:\/\/mdxcro.com\/es\/regulacion-de-las-pruebas-de-laboratorio-desarrolladas-ldt-por-la-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mdxcro.com\/es\/ivd-cro\/"},{"@type":"ListItem","position":2,"name":"Regulaci\u00f3n de las pruebas de laboratorio desarrolladas (LDT) por la FDA"}]},{"@type":"WebSite","@id":"https:\/\/mdxcro.com\/es\/#website","url":"https:\/\/mdxcro.com\/es\/","name":"MDx CRO","description":"Investigaci\u00f3n cl\u00ednica, normativa y control de calidad en tecnolog\u00eda m\u00e9dica y diagn\u00f3stico in vitro","publisher":{"@id":"https:\/\/mdxcro.com\/es\/#organization"},"alternateName":"MDx","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mdxcro.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/mdxcro.com\/es\/#organization","name":"CRO de MDx","url":"https:\/\/mdxcro.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/07\/MDX.svg","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/07\/MDX.svg","width":352,"height":114,"caption":"CRO de MDx"},"image":{"@id":"https:\/\/mdxcro.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/medtech-ivd-cro"]},{"@type":"Person","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/person\/757ac74b94d37b0b3992676bb7e868e4","name":"Carlos Galamba","pronouns":"he","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/10\/cropped-Carlos-Galamba-2-96x96.jpg","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/10\/cropped-Carlos-Galamba-2-96x96.jpg","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/10\/cropped-Carlos-Galamba-2-96x96.jpg","caption":"Carlos Galamba"},"description":"With more than 18 years of experience in the IVD sector, including hands-on work as a scientist in transfusion medicine and infectious disease diagnostics, and regulatory review experience at BSI, one of the EU's largest Notified Bodies, Carlos Galamba brings a uniquely integrated perspective to IVD regulatory strategy. Their work spans Class C\/D IVDs, companion diagnostics, NGS-based assays, and software-based IVDs, with a current advisory role to the European Commission on regulatory matters. At MDx CRO, they lead regulatory strategy for complex IVD programs across EU IVDR, FDA, and global markets.","sameAs":["https:\/\/www.linkedin.com\/in\/carlos-galamba\/","https:\/\/www.youtube.com\/@MDxCRO"]}]}},"_links":{"self":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/8602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/comments?post=8602"}],"version-history":[{"count":2,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/8602\/revisions"}],"predecessor-version":[{"id":9699,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/8602\/revisions\/9699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/media\/5915"}],"wp:attachment":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/media?parent=8602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/categories?post=8602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/tags?post=8602"},{"taxonomy":"resources-sector","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/resources-sector?post=8602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}